Shots:

• EspeRare to get EU development rights of DMX-101- developed under the name ER-004. Dermelix to get WW development & exclusive commercialization rights for EspeRare’s DMX-101 (Ex- Europe)
• In H2’19 Dermelix & EspeRare plans for the onset of clinical study assessing DMX-101 in 15 patients with X-linked hypohidrotic ectodermal dysplasia (XLHED) in the US and Europe
•  EspeRare’s DMX-101 is an EDA molecule consisting of IgG1 Fc sequence linked with EDA TNF binds to the receptor EDAR resulting in activation of the NFϰB signaling pathway and has received EMA’s PRIME & FDA’s OD designation for XLHED 

Ref: EspeRare | Image: Behance